Illumina Inc (NASDAQ:ILMN)
CAPS Rating:
The Company is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.
The Company is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.
Recs
DNA sequencing is moving into mainstream pharma, and Illumina has the market share and technology. They will dominate for the foreseeable future a fast, fast growing market. The Intel of biotech.